456 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00001 | Citropin modified peptide-3 | GLFAVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 6 M |
| dbacp00010 | Citropin modified peptide-5 | GLFDVIKAVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00019 | Citropin modified peptide-7 | GLFDVIKKVAAVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00098 | Citropin modified peptide-11 | GLFDVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00107 | Citropin modified peptide-13 | GLFDVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00116 | Citropin modified peptide-14 | GLFDVIAKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00150 | Citropin modified peptide-15 | GLFAVIKKVASVIKGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00183 | Citropin modified peptide-16 | GLFAVIKKVASVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00217 | Citropin modified peptide-17 | GLFAVIKKVAAVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00252 | Citropin modified peptide-18 | GLFAVIKKVAAVIRRL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00261 | Citropin modified peptide-19 | GLFAVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00270 | Citropin modified peptide-22 | GLFKVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00292 | Citropin modified peptide-23 | GLFKVIKKVAKVIKKL | Amphibian skin secretions | Penetration and disruption of the membrane | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp00323 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 46.2 ± 7.6 μM |
| dbacp00328 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 2.3 ± 0.2 μM |
| dbacp00333 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 30.8 ± 2.0 μM |
| dbacp00338 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : 36.2 ± 2.8 μM |
| dbacp00343 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Chronic myeloid Leukemia | CC50 : 29.0 ± 3.7 μM |
| dbacp00348 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 6.4 ± 0.6 μM |
| dbacp00353 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Chronic myeloid Leukemia | CC50 : 33.3 ±7.4 μM |
| dbacp00358 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Chronic myeloid Leukemia | CC50 : 9.5 ± 0.5 μM |
| dbacp00363 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 51.0 ± 4.6 μM |
| dbacp00368 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 4.6 ± 0.2 μM |
| dbacp00373 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 15.6 ± 3.6 μM |
| dbacp00378 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : > 64 μM |
| dbacp00383 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Chronic myeloid Leukemia | CC50 : 37.5 ± 3.3 μM |
| dbacp00388 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 1.4 ± 0.2 μM |
| dbacp00393 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Chronic myeloid Leukemia | CC50 : 38.5 ± 4.8 μM |
| dbacp00398 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Chronic myeloid Leukemia | CC50 : 15.5 ± 0.8 μM |
| dbacp00404 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 22.5 ± 3.3 μM |
| dbacp00409 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 3.0 ± 0.1 μM |
| dbacp00414 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 14.9 ± 0.8 μM |
| dbacp00419 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : 51.5 ± 3.9 μM |
| dbacp00424 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 3.9 ± 0.2 μM |
| dbacp00429 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Chronic myeloid Leukemia | CC50 : 14.1 ± 0.9 μM |
| dbacp00441 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 19.5 ± 0.5 μM |
| dbacp00446 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 1.7 ± 0.1 μM |
| dbacp00451 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 9.0 ± 0.5 μM |
| dbacp00456 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : 44.2 ± 2.2 μM |
| dbacp00461 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Chronic myeloid Leukemia | CC50 : 6.7 ± 0.7 μM |
| dbacp00466 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 2.1 ± 0.2 μM |
| dbacp00471 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Chronic myeloid Leukemia | CC50 : 9.0 ± 1.1μM |
| dbacp00476 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Chronic myeloid Leukemia | CC50 : 5.1 ± 0.3 μM |
| dbacp00481 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 26.5 ± 2.4 μM |
| dbacp00486 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 2.0 ± 0.1 μM |
| dbacp00491 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 14.7 ± 1.5 μM |
| dbacp00496 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : 20.9 ± 1.4 μM |
| dbacp00501 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Chronic myeloid Leukemia | CC50 : 15.2 ± 1.9 μM |
| dbacp00506 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 1.3 ± 0.1 μM |
| dbacp00511 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Chronic myeloid Leukemia | CC50 : 15.7 ±1.1μM |
| dbacp00516 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Chronic myeloid Leukemia | CC50 : 10.4 ± 1.0 μM |
| dbacp00521 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 29.4 ± 1.1 μM |
| dbacp00526 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 5.0 ± 0.3 μM |
| dbacp00531 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 34.5 ± 3.6 μM |
| dbacp00536 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : 39.4 ± 2.6 μM |
| dbacp00541 | [K8R]cGm | GCRRLCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 3.1 ± 0.1 μM |
| dbacp00546 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 18.3 ± 1.4 μM |
| dbacp00551 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 4.0 ± 0.1 μM |
| dbacp00556 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 25.0 ± 2.9 μM |
| dbacp00561 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : 17.1 ± 0.7 μM |
| dbacp00566 | [L5W]cGm | GCRRWCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 1.0 ± 0.1 μM |
| dbacp00572 | [L9]-P18 | KWKLFKKILKFLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 3 µM |
| dbacp00574 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : > 64 μM |
| dbacp00579 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 10.3 ± 1.1 μM |
| dbacp00584 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 51.2 ± 4.0 μM |
| dbacp00589 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : > 64 μM |
| dbacp00594 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Chronic myeloid Leukemia | CC50 : 48.4 ± 0.7 μM |
| dbacp00599 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 11.5 ± 0.6 μM |
| dbacp00604 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Chronic myeloid Leukemia | CC50 : 34.1 ± 3.9 μM |
| dbacp00609 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Chronic myeloid Leukemia | CC50 : 30.8 ± 2.5 μM |
| dbacp00620 | [S9]-P18 | KWKLFKKISKFLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 3 µM |
| dbacp00622 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 30.3 ± 1.1 μM |
| dbacp00627 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 4.0 ± 0.1 μM |
| dbacp00632 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 68.4 ± 9.6 μM |
| dbacp00637 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : 50.4 ± 2.4 μM |
| dbacp00642 | [Y14W]cGm | GCRRLCYKQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 2.7 ± 0.1 μM |
| dbacp00647 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 31.6 ± 1.3 μM |
| dbacp00652 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 5.4 ± 0.3 μM |
| dbacp00657 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 31.3 ± 2.6 μM |
| dbacp00662 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : 41.0 ± 4.2 μM |
| dbacp00667 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Chronic myeloid Leukemia | CC50 : 15.1 ± 1.4 μM |
| dbacp00672 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 3.9 ± 0.1 μM |
| dbacp00677 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 23.3 ± 0.4 μM |
| dbacp00682 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 5.1 ± 0.3 μM |
| dbacp00687 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 39.7 ± 3.8 μM |
| dbacp00692 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : > 64 μM |
| dbacp00697 | [Y7W]cGm | GCRRLCWKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 3.9 ± 0.2 μM |
| dbacp00701 | 072RB | DMRPEIYI(Aib)QELRRIGDAFN(Aib)YRQIKIWFQNRRMKWKK | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Jurkat | Leukemia | Not found |
| dbacp00702 | 072RB | DMRPEIYI(Aib)QELRRIGDAFN(Aib)YRQIKIWFQNRRMKWKK | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Namalwa | Leukemia | Not found |
| dbacp00703 | 072RB | DMRPEIYI(Aib)QELRRIGDAFN(Aib)YRQIKIWFQNRRMKWKK | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | U937 | Leukemia | Not found |
| dbacp00718 | 2XAkt-in | VTDHPDRLWAWEKGGGVTDHPDRLWAWEK | Not found | Inducing apoptosis | Cell death assay | T4 | Leukemia | Not found |
| dbacp00951 | ABP-dHC-Cecropin A | RWKIFKKIERVGQNVRDGIIKAGPAIQVLGTAKALGK | Synthetic construct | Apoptosis inducing | MTT assay | K562 cells | Leukemia | IC50 : 349.5 μM |
| dbacp00952 | ABP-dHC-Cecropin A | RWKIFKKIERVGQNVRDGIIKAGPAIQVLGTAKALGK | Synthetic construct | Apoptosis inducing | MTT assay | U937 cells | Leukemia | IC50 : 303.2 μM |
| dbacp00953 | ABP-dHC-Cecropin A | RWKIFKKIERVGQNVRDGIIKAGPAIQVLGTAKALGK | Synthetic construct | Apoptosis inducing | MTT assay | THP-1 cells | Leukemia | IC50 : 228.5 μM |
| dbacp00954 | ABP-dHC-Cecropin A-K | RWKIFKKIERVGQNVRDGIIKAGKAIQVLGTAKALGK | Synthetic construct | Apoptosis inducing | MTT assay | K562 cells | Leukemia | IC50 : 349.5 μM |
| dbacp00955 | ABP-dHC-Cecropin A-K | RWKIFKKIERVGQNVRDGIIKAGKAIQVLGTAKALGK | Synthetic construct | Apoptosis inducing | MTT assay | U937 cells | Leukemia | IC50 : 303.2 μM |
| dbacp00956 | ABP-dHC-Cecropin A-K | RWKIFKKIERVGQNVRDGIIKAGKAIQVLGTAKALGK | Synthetic construct | Apoptosis inducing | MTT assay | THP-1 cells | Leukemia | IC50 : 228.5 μM |
| dbacp00992 | Akt-in | AVTDHPDRLWAWEKF | Not found | Inducing apoptosis | Co-immunoprecipitation, GST Pull-down,GST Competition, In Vitro Akt Kinase, PKA Kinase, In Vitro PDK1 Kinase, PtdIns(3,4,5)P3 Lipid-Protein Pull-down, Proliferation assay, Cell Death assay and Mitochondrial Permeability Transition assay | T4 | T-cell Leukemia | Not found |
| dbacp01000 | Alloferon 1 | HGVSGHGQHGVHG | Blow fly | Immune modulation | Cytotoxicity assay | P388 | Murine leukemia | Activity : 25 µg |
| dbacp01002 | Alloferon 2 | GVSGHGQHGVHG | Blue blowfly | Immune modulation | Cytotoxicity assay | P388 | Murine leukemia | Activity : 25 µg |
| dbacp01004 | Alloferon-1 | HGVSGHGHQHGVHG | Blue blowfly | Immune modulation | Anti-tumor activity assay | P388 | Murine leukemia | Not found |
| dbacp01005 | Alloferon-1 [Cleaved into: Alloferon-2] | HGVSGHGQHGVHG | Blue blowfly | Immune modulation | Cytotoxicity assay | P388 | Murine leukemia | Activity : 25 µg |
| dbacp01172 | Antp-LP4 | RQIKIWFQNRRMKWKKSWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Apoptosis inducing | Not specified | CLL | Leukemia | IC50 : 0.7 ± 0.1 µM |
| dbacp01173 | Antp-LP4 | RQIKIWFQNRRMKWKKSWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Apoptosis inducing | Not specified | MEC-1 | Leukemia | IC50 : 2.5 ± 0.1 µM |
| dbacp01212 | ATP-binding cassette sub-family C member 3 | MDALCGSGELGSKFWDSNLSVHTENPDLTPCFQNSLLAWVPCIYLWVALPCYLLYLRHHCRGYIILSHLSKLKMVLGVLLWCVSWADLFYSFHGLVHGRAPAPVFFVTPLVVGVTMLLATLLIQYERLQGVQSSGVLIIFWFLCVVCAIVPFRSKILLAKAEGEISDPFRFTTFYIHFALVLSALILACFREKPPFFSAKNVDPNPYPETSAGFLSRLFFWWFTKMAIYGYRHPLEEKDLWSLKEEDRSQMVVQQLLEAWRKQEKQTARHKASAAPGKNASGEDEVLLGARPRPRKPSFLKALLATFGSSFLISACFKLIQDLLSFINPQLLSILIRFISNPMAPSWWGFLVAGLMFLCSMMQSLILQHYYHYIFVTGVKFRTGIMGVIYRKALVITNSVKRASTVGEIVNLMSVDAQRFMDLAPFLNLLWSAPLQIILAIYFLWQNLGPSVLAGVAFMVLLIPLNGAVAVKMRAFQVKQMKLKDSRIKLMSEILNGIKVLKLYAWEPSFLKQVEGIRQGELQLLRTAAYLHTTTTFTWMCSPFLVTLITLWVYVYVDPNNVLDAEKAFVSVSLFNILRLPLnMLPQLISNLTQASVSLKRIQQFLSQEELDPQSVERKTISPGYAITIHSGTFTWAQDLPPTLHSLDIQVPKGALVAVVGPVGCGKSSLVSALLGEMEKLEGKVHMKGSVAYVPQQAWIQNCTLQENVLFGKALNPKRYQQTLEACALLADLEMLPGGDQTEIGEKGINLSGGQRQRVSLARAVYSDADIFLLDDPLSAVDSHVAKHIFDHVIGPEGVLAGKTRVLVTHGISFLPQTDFIIVLADGQVSEMGPYPALLQRNGSFANFLCNYAPDEDQGHLEDSWTALEGAEDKEALLIEDTLSNHTDLTDNDPVTYVVQKQFMRQLSALSSDGEGQGRPVPRRHLGPSEKVQVTEAKADGALTQEEKAAIGTVELSVFWDYAKAVGLCTTLAICLLYVGQSAAAIGANVWLSAWTNDAMADSRQNNTSLRLGVYAALGILQGFLVMLAAMAMAAGGIQAARVLHQALLHNKIRSPQSFFDTTPSGRILNCFSKDIYVVDEVLAPVILMLLNSFFNAISTLVVIMASTPLFTVVILPLAVLYTLVQRFYAATSRQLKRLESVSRSPIYSHFSETVTGASVIRAYNRSRDFEIISDTKVDANQRSCYPYIISNRWLSIGVEFVGNCVVLFAALFAVIGRSSLNPGLVGLSVSYSLQVTFALNWMIRMMSDLESNIVAVERVKEYSKTETEAPWVVEGSRPPEGWPPRGEVEFRNYSVRYRPGLDLVLRDLSLHVHGGEKVGIVGRTGAGKSSMTLCLFRILEAAKGEIRIDGLNVADIGLHDLRSQLTIIPQDPILFSGTLRMNLDPFGSYSEEDIWWALELSHLHTFVSSQPAGLDFQCSEGGENLSVGQRQLVCLARALLRKSRILVLDEATAAIDLETDNLIQATIRTQFDTCTVLTIAHRLNTIMDYTRVLVLDKGVVAEFDSPANLIAARGIFYGMARDAGLA | Human | Antiproliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | HL60 | Leukemia cells | IC50 ± SD : 9.3 ± 2.9μM |
| dbacp01216 | ATP-binding cassette sub-family C member 5 | MKDIDIGKEYIIPSPGYRSVRERTSTSGTHRDREDSKFRRTRPLECQDALETAARAEGLSLDASMHSQLRILDEEHPKGKYHHGLSALKPIRTTSKHQHPVDNAGLFSCMTFSWLSSLARVAHKKGELSMEDVWSLSKHESSDVNCRRLERLWQEELNEVGPDAASLRRVVWIFCRTRLILSIVCLMITQLAGFSGPAFMVKHLLEYTQATESNLQYSLLLVLGLLLTEIVRSWSLALTWALNYRTGVRLRGAILTMAFKKILKLKNIKEKSLGELINICSNDGQRMFEAAAVGSLLAGGPVVAILGMIYNVIILGPTGFLGSAVFILFYPAMMFASRLTAYFRRKCVAATDERVQKMNEVLTYIKFIKMYAWVKAFSQSVQKIREEERRILEKAGYFQSITVGVAPIVVVIASVVTFSVHMTLGFDLTAAQAFTVVTVFNSMTFALKVTPFSVKSLSEASVAVDRFKSLFLMEEVHMIKNKPASPHIKIEMKNATLAWDSSHSSIQNSPKLTPKMKKDKRASRGKKEKVRQLQRTEHQAVLAEQKGHLLLDSDERPSPEEEEGKHIHLGHLRLQRTLHSIDLEIQEGKLVGICGSVGSGKTSLISAILGQMTLLEGSIAISGTFAYVAQQAWILNATLRDNILFGKEYDEERYNSVLNSCCLRPDLAILPSSDLTEIGERGANLSGGQRQRISLARALYSDRSIYILDDPLSALDAHVGNHIFNSAIRKHLKSKTVLFVTHQLQYLVDCDEVIFMKEGCITERGTHEELMNLNGDYATIFNNLLLGETPPVEINSKKETSGSQKKSQDKGPKTGSVKKEKAVKPEEGQLVQLEEKGQGSVPWSVYGVYIQAAGGPLAFLVIMALFMLNVGSTAFSTWWLSYWIKQGSGNTTVTRGNETSVSDSMKDNPHMQYYASIYALSMAVMLILKAIRGVVFVKGTLRASSRLHDELFRRILRSPMKFFDTTPTGRILNRFSKDMDEVDVRLPFQAEMFIQNVILVFFCVGMIAGVFPWFLVAVGPLVILFSVLHIVSRVLIRELKRLDNITQSPFLSHITSSIQGLATIHAYNKGQEFLHRYQELLDDNQAPFFLFTCAMRWLAVRLDLISIALITTTGLMIVLMHGQIPPAYAGLAISYAVQLTGLFQFTVRLASETEARFTSVERINHYIKTLSLEAPARIKNKAPSPDWPQEGEVTFENAEMRYRENLPLVLKKVSFTIKPKEKIGIVGRTGSGKSSLGMALFRLVELSGGCIKIDGVRISDIGLADLRSKLSIIPQEPVLFSGTVRSNLDPFNQYTEDQIWDALERTHMKECIAQLPLKLESEVMENGDNFSVGERQLLCIARALLRHCKILILDEATAAMDTETDLLIQETIREAFADCTMLTIAHRLHTVLGSDRIMVLAQGQVVEFDTPSVLLSNDSSRFYAMFAAAENKVAVKG | Human | Antiproliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | HL60 | Leukemia | IC50 ± SD : 9.3 ± 2.9 μM |
| dbacp01252 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10 µM |
| dbacp01261 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10 µM |
| dbacp01271 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10 µM |
| dbacp01281 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10-100 µM |
| dbacp01292 | Aurein-1.3 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | MOLT-4 | Leukemia | IC50 : 4-5 μM |
| dbacp01329 | Aurein-2.5 | GLFDIVKKVVGAFGSL | Green and golden bell frog | Cell membrane disintegration | One-dose and five-dose assay | K-562 | Leukemia | IC50 : 4-5 μM |
| dbacp01347 | Aurein-2.7 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | RPMI-8226 | Leukemia | IC50 : 4-5 μM |
| dbacp01356 | Aurein-2.7 | GLFDIVKKIAGHIVSSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | SR | Leukemia | IC50 : 4-5 μM |
| dbacp01358 | Aurein-3.1 [Cleaved into: Aurein-3.1.1; Aurein-3.1.2] | GLFDIVKKIAGHIAGSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | CCRF-CEM | Leukemia | IC50 : 4-5 μM |
| dbacp01371 | Aurein-3.2 | GLFDIVKKIAGHIASSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | HL-60(TB) | Leukemia | IC50 : 4-5 μM |
| dbacp01406 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10-100 µM |
| dbacp01415 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10-100 µM |
| dbacp01424 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Leukemia tumor cell line | Leukemia cancer | LC50 : 10-100 µM |
| dbacp01605 | BIM | RPEIWIAQELRRIGDEFNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Leukemia | Not found |
| dbacp01712 | BIM FA1 | RPEIWIAQELRRAGDVLNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Leukemia | Not found |
| dbacp01714 | BIM FD1 | RPEIWLAQYLRRLGDQINAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Leukemia | Not found |
| dbacp01716 | BIM FD2 | RPEIWMAQVLRRFGDLLNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Leukemia | Not found |
| dbacp01718 | BIM FW1 | RPEIWIAQGLRRIGDTWNAYYAR | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Not found | Leukemia | Not found |
| dbacp01834 | Bim-BH3W89Y | DMRPEIYIAQELRRIGDEFNAY | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Jurkat | Leukemia | Not found |
| dbacp01835 | Bim-BH3W89Y | DMRPEIYIAQELRRIGDEFNAY | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Namalwa | Leukemia | Not found |
| dbacp01836 | Bim-BH3W89Y | DMRPEIYIAQELRRIGDEFNAY | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | U937 | Leukemia | Not found |
| dbacp01837 | Bim-BH3YA2Aib | DMRPEIYI(Aib)QELRRIGDAFN(Aib)Y | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Jurkat | Leukemia | Not found |
| dbacp01838 | Bim-BH3YA2Aib | DMRPEIYI(Aib)QELRRIGDAFN(Aib)Y | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | Namalwa | Leukemia | Not found |
| dbacp01839 | Bim-BH3YA2Aib | DMRPEIYI(Aib)QELRRIGDAFN(Aib)Y | BH3-only, Direct activators, BIM analogues | Inducing apoptosis | Not specified | U937 | Leukemia | Not found |
| dbacp01840 | BIRD-2 (Bcl-2 IP3R disrupter 2) | RKKRRQRRRGGNVYTEIKCNSLLPLAAIVRV | Not found | Inducing apoptosis | MTT assay | DLBCL | Leukemia | Not found |
| dbacp01841 | BIRD-2 (Bcl-2 IP3R disrupter 2) | RKKRRQRRRGGNVYTEIKCNSLLPLAAIVRV | Not found | Inducing apoptosis | MTT assay | CLL | Leukemia | Not found |
| dbacp01913 | BpirLAAO-I | ADDKNPLEEFRETNYEVFLEIAKNGLKATSNPKRVVIVGAGMAGLSAAY | Venom base | Inducing apoptosis | MTT assay | Jurkat | Acute T cell Leukemia | Not found |
| dbacp01959 | Brevinin-2R | KLKNFAKGVAQSLLNKASCKLSGQC | Skin, Marsh frog, Europe | Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death | MTT-assay | Jurkat | T-cell Leukemia | LD50 : 10 – 15 μg/ml |
| dbacp01960 | Brevinin-2R | KLKNFAKGVAQSLLNKASCKLSGQC | Skin, Marsh frog, Europe | Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death | MTT-assay | Jurkat | T-cell Leukemia | LD50 : 20 – 25 μg/ml |
| dbacp01961 | Brevinin-2R | KLKNFAKGVAQSLLNKASCKLSGQC | Skin, Marsh frog, Europe | Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death | MTT-assay | Jurkat | T-cell Leukemia | LD50 : 30 – 40 μg/ml |
| dbacp01980 | Brevinin-2R | KLKNFAKGVAQSLLNKASCKLSGQC | Skin, Marsh frog, Europe | Activates the lysosomal-mitochondrial death pathway; Involves autophagy-like cell death | MTT-assay | Jurkat | T-cell Leukemia | LD50 : 20 – 25 µg/mll |
| dbacp01989 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 14.7 µg/ml |
| dbacp01990 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 11.3 µg/ml |
| dbacp01991 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 8.2 µg/ml |
| dbacp01992 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | MOLT-4 | Leukemia cancer | IC50 : 17 µg/ml |
| dbacp01993 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | RPMI-8226 | Leukemia cancer | IC50 : 10.5 µg/ml |
| dbacp01994 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | SR | Leukemia cancer | IC50 : 20.2 µg/ml |
| dbacp02115 | C-1 | KWKLFKKIPFLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 31 µM |
| dbacp02118 | C-10 | KWKLFKKIPKFLH | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : <100 µM |
| dbacp02121 | C-2 | KWKLFKKIPKFLHLAKK | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 23 µM |
| dbacp02124 | C-3 | KWKLFKKIPLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 62 µM |
| dbacp02127 | C-4 | KWKLFKKIPKFLHLAK | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 25 µM |
| dbacp02130 | C-5 | KWKLFKKIPHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 67 µM |
| dbacp02133 | C-6 | KWKLFKKIPKFLHLA | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 27 µM |
| dbacp02136 | C-7 | KWKLFKKIPLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : <100 µM |
| dbacp02139 | C-8 | KWKLFKKIPKFLHL | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 30 µM |
| dbacp02142 | C-9 | KWKLFKKIPLKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : <100 µM |
| dbacp02231 | CA-MA | KWKLFKKIGIGKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 65 µM |
| dbacp02240 | CA-MA-P | KWKLFKKIPKFLHSAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 25 µM |
| dbacp02241 | CA-MA1 | KWKLFKKIKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 85.3 µM |
| dbacp02245 | CA-MA2 | KWKLFKKIPKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 35.1 µM |
| dbacp02249 | CA-MA3 | KWKLFKKIGPGKFLHSAKKF | Ceropin-African clawed frog hybrid peptides | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : >100 µM |
| dbacp02310 | Cathelicidin antimicrobial peptide | MKTQRDGHSLGRWSLVLLLLGLVMPLAIIAQVLSYKEAVLRAIDGINQRSSDANLYRLLDLDPRPTMDGDPDTPKPVSFTVKETVCPRTTQQSPEDCDFKKDGLVKRCMGTVTLNQARGSFDISCDKDNKRFALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | Human | Antiproliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | HL60 | Leukemia cells | IC50 ± SD : 9.3 ± 2.9μM |
| dbacp02323 | Cecropin 2 | GWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLK | The Medfly, also housefly | Cell membrane disintegration | Not specified | Not found | Leukemia cancer | Not found |
| dbacp02324 | Cecropin 2 | GWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLK | Mediterranean fruit fly | Not specified | Not specified | Not found | Leukemia cancer | Not found |
| dbacp02325 | Cecropin 2 | GWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLK | The Medfly, also housefly | Cell membrane disintegration | Not specified | Not found | Leukemia cancer | Not found |
| dbacp02357 | Cecropin B | KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL | Silkmoth | Pore formation at the cytoplasmic membrane | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 15.5 µM |
| dbacp02361 | Cecropin B | KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL | Silkmoth | Pore formation at the cytoplasmic membrane | MTT/MTS assay | WEHI-3B | Leukemia cancer | IC50 : 4.4 µM |
| dbacp02371 | Cecropin P1 | SWLSKTAKKLENSAKKRISEGIAIAIQGGPR | Small Intestine of Pig | Pore formation at the cytoplasmic membrane | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 93 µM |
| dbacp02377 | Cepafungin complex | I-C28H46N4O6,II-C27H44N4O6,III-C26H42N4O6 | Culture broth of strain, common, free-living bacterium, **Pseudomonas sp.** | Not specified | Not specified | P-388 | Leukemia cancer | Not found |
| dbacp02396 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid leukemia | CC50 : 39.8 ± 1.0 μM |
| dbacp02401 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid leukemia | CC50 : 2.9 ± 0.1 μM |
| dbacp02406 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid leukemia | CC50 : 71.7 ± 9.2 μM |
| dbacp02411 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid leukemia | CC50 : > 64 μM |
| dbacp02416 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Chronic myeloid leukemia | CC50 : 15.3 ± 1.4 μM |
| dbacp02421 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid leukemia | CC50 : 2.7 ± 0.1 μM |
| dbacp02426 | cGm (Derived from Gm) | GCRRLCYKQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Chronic myeloid leukemia | CC50 : 12.7 ± 1.1 μM |
| dbacp02478 | ChMAP-28 | GRFKRFRKKLKRLWHKVGPFVGPILHY | Domestic goat | Cause cell membrane permeability; Induce necrotic death | Cytotoxic Activity assay, Lactate dehydrogenase (LDH)-Releaseassay, MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : 3.39 ± 0.15 μM |
| dbacp02488 | Citropin 1.1 | GLFDVIKKVASVIGGL | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp02499 | Citropin 1.1D | glfdvikkvasviggl | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp02564 | CRAMP-18 E2K | GKKLKKIGQKIKNFFQKL | Synthetic | Disrupt cell membrane structure | MTT assay | K-562 | Chronic myelogenous Leukemia | IC50 : 20–34 uM |
| dbacp02565 | CRAMP-18 E2K | GKKLKKIGQKIKNFFQKL | Synthetic | Disrupt cell membrane structure | MTT assay | Jurkat | Acute T cell Leukemia | IC50 : 20–34 uM |
| dbacp02566 | CRAMP-18 E2K | GKKLKKIGQKIKNFFQKL | Synthetic | Disrupt cell membrane structure | MTT assay | K-549 | Acute T cell Leukemia | IC50 : 20–34 uM |
| dbacp02594 | Cyclic [W(RW)4 ]-Dox | WRWRWRWRW | Not found | Inhibition of the cell proliferation | MTT/MTS assay | CCRF-CEM | Leukemia cancer | 62-73% inhibition of cell proliferation at 1 µM |
| dbacp02608 | Cytotoxin drCT-1 | LKCNKLVPLFYKTCPAGKNL | Not found | Inducing apoptosis | MTT assay | U937 | Leukemia | IC50 : 8.9 µg/ml |
| dbacp02609 | Cytotoxin drCT-1 | LKCNKLVPLFYKTCPAGKNL | Not found | Inducing apoptosis | MTT assay | K562 | Leukemia | IC50 : 6.7 µg/ml |
| dbacp02618 | D-Antp-LP4 | RQIKIWFQNRRMKWKKSWTWEKKLETAVNLAWTAGNSNKWTWK | Not found | Inducing apoptosis | Not specified | CLL | Leukemia | IC50 : 0.7 ± 0.4 µM |
| dbacp02619 | D-Antp-LP4 | RQIKIWFQNRRMKWKKSWTWEKKLETAVNLAWTAGNSNKWTWK | Not found | Inducing apoptosis | Not specified | MEC-1 | Leukemia | IC50 : 1.6 ± 0.3 µM |
| dbacp02623 | D-MinAntp-LP4 | KRRMKWKKSWTWEKKLETAVNLAWTAGNSNKWTWK | Not found | Inducing apoptosis | Not specified | CLL | Leukemia | IC50 : 0.6 ± 0.2 µM |
| dbacp02624 | D-MinAntp-LP4 | KRRMKWKKSWTWEKKLETAVNLAWTAGNSNKWTWK | Not found | Inducing apoptosis | Not specified | MEC-1 | Leukemia | IC50 : 1.4 ± 0.1 µM |
| dbacp02625 | D-N-Ter-Antp | MAVPPTYADLGKSARDVFTKGYGFGLRQIKIWFQNRRMKWKK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | CLL | Leukemia | IC50 : 1.5 ± 0.6 µM |
| dbacp02626 | D-N-Ter-Antp | MAVPPTYADLGKSARDVFTKGYGFGLRQIKIWFQNRRMKWKK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | MEC-1 | Leukemia | IC50 : 2.2 ± 1.6 µM |
| dbacp02645 | Defensin-like protein (Sesquin) | KTCENLADTY | Yard-Long bean | Anti-proliferative action | MTT assay | MCF-7 | Leukemia | MIC : 0.25 μg/ml |
| dbacp02805 | Dolastatin 10 | 2-[[2-(dimethylamino)-3-methylbutanoyl]amino]-N-[3-methoxy-1-[2-[1-methoxy-2-methyl-3-oxo-3-[[2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutaNAmide | Wedge sea hare | Apoptosis inducing | Cell viability assay | SR | Leukemia cancer | IC50 : 0.0013 - 0.013 nM |
| dbacp02809 | Dolastatin 15 | VV-nMe-VPP-2hydroxyisovaleryl-2-oxo-4-methoxy-5-benzyl-3-pyrroline | Wedge sea hare | Apoptosis inducing | Cell viability assay | SR | Leukemia cancer | IC50 : 0.0013 - 0.013 nM |
| dbacp02871 | Epinecidin-1 | GFIFHIIKGLFHAGKMIHGLV | Not found | Inducing apoptosis | MTT assay | U937 | Leukemia | Not found |
| dbacp02930 | Figainin 1 | FIGTLIPLALGALTKLFK | Chaco tree frog | Membrane disruption and cell lysis | MTT/MTS assay | B16F10 | Leukemia | IC50 : 10.5 µM |
| dbacp02946 | Figainin 1 | FIGTLIPLALGALTKLFK | Skin secretions, Chaco tree frog, South America | Membrane disruption | MTT/MTS assay | B16F10 | Leukemia | IC50 : 10.5 µM |
| dbacp03126 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Fluorescence-based assay using a Fluorescence Imaging Plate Reader | K-562 | Chronic myeloid leukemia | CC50 : 3.8 ± 0.3 μM |
| dbacp03130 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid leukemia | CC50 : 3.8 ± 0.3 μM |
| dbacp03135 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid leukemia | CC50 : 67.0 ± 5.0 μM |
| dbacp03140 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid leukemia | CC50 : 3.7 ± 0.2 μM |
| dbacp03145 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid leukemia | CC50 : 49.9 ±16.6 μM |
| dbacp03150 | Gomesin | ZCRRLCYKQRCVTYCRGR | Tarantula spider sp. | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid leukemia | CC50 : 54.1 ± 5.0 μM |
| dbacp03191 | HAL-1 | GMWSKILGHLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 49 ± 9 µM |
| dbacp03194 | HAL-1/10 | GMWKKILGKLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03197 | HAL-1/12 | GKWSKILGHLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : > 40 µM |
| dbacp03200 | HAL-1/15 | GMWSKLLGHLLR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : > 40 µM |
| dbacp03203 | HAL-1/17 | KMWSKILGHLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03206 | HAL-1/18 | GMWSKILKHLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03209 | HAL-1/19 | GKWKKILGHLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03212 | HAL-1/20 | GKWSKILGKLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : > 40 µM |
| dbacp03215 | HAL-1/21 | GKWKKILGKLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03218 | HAL-1/22 | gmwskilghlir | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03221 | HAL-1/29 | GMWSKILGHLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03224 | HAL-1/4 | GMWSKILGHLKR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03227 | HAL-1/5 | GMWKKILGHLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : > 40 µM |
| dbacp03230 | HAL-1/6 | GMWSKILGHLIK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03233 | HAL-1/9 | GMWSKILGKLIR | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 30 ± 10 µM |
| dbacp03236 | HAL-2 | GKWMSLLKHILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 34 µM |
| dbacp03239 | HAL-2/1 | GKWKSLLKHILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : > 40 µM |
| dbacp03242 | HAL-2/11 | GKWLSLLKHILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03245 | HAL-2/13 | GKWMTLLKHILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03248 | HAL-2/18 | GKWMSLLKHIWK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03251 | HAL-2/19 | GKWMSLLKHWLK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03254 | HAL-2/2 | GKWMKLLKHILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : > 40 µM |
| dbacp03257 | HAL-2/20 | GKWMSLWKHILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03260 | HAL-2/22 | gkwmsllkhilk | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03263 | HAL-2/24 | GKFMSLLKHILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03266 | HAL-2/4 | GKWMSLLKKILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03269 | HAL-2/6 | GKWMSFLKHILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03272 | HAL-2/8 | GKWMSLLKHILK | Sweat bees and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp03279 | Harmoniasin | IGGYCSELDL-NH | Harlequin lady beetle | Induce apoptotic and necrotic cell deaths | MTS assay and LDH release assay | U937 | Human leukemia | MIC : approx. 200 µg/ml |
| dbacp03280 | Harmoniasin | IGGYCSELDL-NH | Harlequin lady beetle | Induce apoptotic and necrotic cell deaths | MTS assay and LDH release assay | Jurkat | Human leukemia | MIC : approx. 200 µg/ml |
| dbacp03406 | Interferon gamma (IFN-gamma) | MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQIISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQLLPESSLRKRKRSRC | Mouse | Anti-proliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | HL60 | Leukemia | IC50 ± SD : 9.3 ± 2.9μM |
| dbacp03471 | IP3R-derived peptide (IDP) | NVYTEIKCNSLLPLDDIVRV | Not found | Inducing apoptosis | Not specified | CLL | Leukemia | Not found |
| dbacp03541 | L-amino-acid oxidase (BatroxLAAO) (LAO) (EC 1.4.3.2) | MNVFFTFSLLFLAALGSCADDRNPLEECFRETDYEEFLEIAKNGLSTTSNPKRVVIVGAGMSGLSAAYVLANAGHQVTVLEASERAGGRVKTYRNEKEGWYANLGPMRLPEKHRIVREYIRKFDLQLNEFSQENENAWYFIKNIRKRVGEVNKDPGVLEYPVKPSEVGKSAGQLYEESLQKAVEELRRTNCSYMLNKYDTYSTKEYLLKEGNLSPGAVDMIGDLLNEDSGYYVSFIESLKHDDIFAYEKRFDEIVGGMDKLPTSMYQAIQEKVHLNARVIKIQQDVKEVTVTYQTSEKETLSVTADYVIVCTTSRAARRIKFEPPLPPKKAHALRSVHYRSGTKIFLTCTKKFWEDDGIHGGKSTTDLPSRFIYYPNHNFPNGVGVIIAYGIGDDANYFQALDFEDCGDIVINDLSLIHQLPKEEIQAICRPSMIQRWSLDKYAMGGITTFTPYQFQHFSEALTAPVDRIYFAGEYTAQAHGWIDSTIKSGLRAARDVNRASEIKK | Common lancehead | Inducing apoptosis | MTT assay | Jurkat | Acute T-cell Leukemia | Not found |
| dbacp03709 | Laxaphycin A | Aoc-Hse-E-Dhb-Hyp-Hse-FLIILG | Terrestrial blue-green alga or the marine cyanobacterium | Not specified | Cell viability assay | CEM-WT | Leukemia cancer | No inhibition at 4 µM |
| dbacp03710 | Laxaphycin A | Aoc-Hse-E-Dhb-Hyp-Hse-FLIILG | Terrestrial blue-green alga or the marine cyanobacterium | Not specified | Cell viability assay | CEM-VLB | Leukemia cancer | No inhibition at 4 µM |
| dbacp03711 | Laxaphycin A | Aoc-Hse-E-Dhb-Hyp-Hse-FLIILG | Terrestrial blue-green alga or the marine cyanobacterium | Not specified | Cell viability assay | CEM-VM1 | Leukemia cancer | No inhibition at 4 µM |
| dbacp03712 | Laxaphycin B | A-Hleu-QN-MeIle-Hasn-TPLT-Ade-V-Hleu | Terrestrial blue-green alga or the marine cyanobacterium | Not specified | Cell viability assay | CEM-WT | Leukemia cancer | 50% inhibition at 1 µM |
| dbacp03713 | Laxaphycin B | A-Hleu-QN-MeIle-Hasn-TPLT-Ade-V-Hleu | Terrestrial blue-green alga or the marine cyanobacterium | Not specified | Cell viability assay | CEM-WT | Leukemia cancer | 44% inhibition at 1 µM |
| dbacp03714 | Laxaphycin B | A-Hleu-QN-MeIle-Hasn-TPLT-Ade-V-Hleu | Terrestrial blue-green alga or the marine cyanobacterium | Not specified | Cell viability assay | CEM-VM1 | Leukemia cancer | 44% inhibition at 1 µM |
| dbacp03715 | Laxaphycin B | A-Hleu-QN-MeIle-Hasn-TPLT-Ade-V-Hleu | Terrestrial blue-green alga or the marine cyanobacterium | Not specified | Cell viability assay | CEM-VLB | Leukemia cancer | 44% inhibition at 1 µM |
| dbacp03716 | Laxaphycin B | A-Hleu-QN-MeIle-Hasn-TPLT-Ade-V-Hleu | Terrestrial blue-green alga or the marine cyanobacterium | Not specified | Cell viability assay | CEM-WT | Leukemia cancer | 40% inhibition at 1 µM |
| dbacp03717 | Laxaphycin B | A-Hleu-QN-MeIle-Hasn-TPLT-Ade-V-Hleu | Terrestrial blue-green alga or the marine cyanobacterium | Not specified | Cell viability assay | CEM-VM1 | Leukemia cancer | 40% inhibition at 1 µM |
| dbacp03718 | Laxaphycin B | A-Hleu-QN-MeIle-Hasn-TPLT-Ade-V-Hleu | Terrestrial blue-green alga or the marine cyanobacterium | Not specified | Cell viability assay | CEM-VLB | Leukemia cancer | 40% inhibition at 1 µM |
| dbacp03741 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | Jurkat | Leukemia | Not found |
| dbacp03742 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | MCF-7 | Leukemia | Not found |
| dbacp03743 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | Colo-35 | Leukemia | Not found |
| dbacp03744 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | MDA-MB-435 | Leukemia | Not found |
| dbacp03745 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | SKov3 | Leukemia | Not found |
| dbacp03746 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | CAov3 | Leukemia | Not found |
| dbacp03747 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | HT-29 | Leukemia | Not found |
| dbacp03748 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | T-47D | Leukemia | Not found |
| dbacp03749 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | CCRF-CEM | Leukemia | Not found |
| dbacp03750 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | K562 | Leukemia | Not found |
| dbacp03751 | LfcinB (Bovine lactoferricin) | FKCRRWQWRM | Not found | Inducing apoptosis | MTT assay | Raji | Leukemia | Not found |
| dbacp04103 | linear (RW)4-Dox | RWRWRWRW | Doxorubicin (Dox) is a well-known anthracycline which has been conjugated to a CPP | Inhibition of the cell proliferation | MTT/MTS assay | CCRF-CEM | Leukemia cancer | 46-69% anti-proliferative activity at 1 µM |
| dbacp04182 | LL-III | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 5 ± 3 µM |
| dbacp04185 | LL-III/1 | VNWKKILAKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 3 ± 1 µM |
| dbacp04188 | LL-III/10 | KNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 9 µM |
| dbacp04191 | LL-III/11 | VNWKKIILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 4 ± 1 µM |
| dbacp04194 | LL-III/12 | vnwkkilgkiikvvk | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 5 ± 2 µM |
| dbacp04197 | LL-III/15 | VNFKKLLGKLLKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 9 ± 3 µM |
| dbacp04200 | LL-III/16 | VN-NAl-KKLLGKLLKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp04203 | LL-III/17 | VNWRRILGRIIRVVR | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp04206 | LL-III/18 | KNWKKILKKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 7 ± 2 µM |
| dbacp04209 | LL-III/19 | VNWKK-Aib-LGK-Aib-IK-Aib-VK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 8 ± 2 µM |
| dbacp04212 | LL-III/2 | NVWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 7 ± 2 µM |
| dbacp04215 | LL-III/22 | KNWKK-Aib-LKK-Aib-IK-Aib-VK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 25 ± 4 µM |
| dbacp04218 | LL-III/23 | VNWKKLLGKLLKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 6 µM |
| dbacp04221 | LL-III/24 | VNWOOILGOIIOVVO | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 5 ± 2 µM |
| dbacp04224 | LL-III/25 | vnwkkllgkllkvvk | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 4 µM |
| dbacp04227 | LL-III/26 | VYWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 6 µM |
| dbacp04230 | LL-III/27 | VNWKKVLGKVVKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 18 µM |
| dbacp04233 | LL-III/3 | VNWKKILKKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp04236 | LL-III/34 | NKWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 5 ± 3 µM |
| dbacp04239 | LL-III/36 | VNWKKILAKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp04242 | LL-III/37 | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 4 ± 1 µM |
| dbacp04245 | LL-III/4 | VNWKKILGKIKKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 18 µM |
| dbacp04248 | LL-III/6 | VNWKKILPKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 6 ± 3 µM |
| dbacp04251 | LL-III/8 | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 9 µM |
| dbacp04254 | LL-III/9 | VNWKKILGKIIKVVK | Lasioglossin III and its analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | Not found |
| dbacp04287 | LP-4 peptide | SWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | CLL | Leukemia | Not found |
| dbacp04288 | LP-4 peptide | SWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | MEC-1 | Leukemia | Not found |
| dbacp04378 | MAC1 | GFGMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 12 ± 6 µM |
| dbacp04381 | MAC1/1 | gfgmalkllkkvl | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 11 µM |
| dbacp04384 | MAC1/10 | GFKMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 16 µM |
| dbacp04387 | MAC1/16 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 70 µM |
| dbacp04390 | MAC1/19 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 43 ± 11 µM |
| dbacp04393 | MAC1/2 | AFGMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 17 µM |
| dbacp04396 | MAC1/20 | GFGMALOLLOOVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 25 ± 3 µM |
| dbacp04399 | MAC1/21 | GFGMALRLLRRVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 22 ± 4 µM |
| dbacp04402 | MAC1/24 | GFGMALKL-(AC6C)-KKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 11 µM |
| dbacp04405 | MAC1/25 | GFGMALK-(AC6C)-LKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 12 ± 2 µM |
| dbacp04408 | MAC1/26 | GFGMA-(AC6C)-KLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 9 ± 2 µM |
| dbacp04411 | MAC1/3 | LFGMALKLLKKVL | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 22 µM |
| dbacp04414 | MAC1/4 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 29 µM |
| dbacp04417 | MAC1/6 | GFGMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 15 µM |
| dbacp04420 | MAC1/9 | GFKMALKLLKKVL-NH2 | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 14 ± 4 µM |
| dbacp04423 | MAC2 | GTGLPMSERRKIMLMMR | Wallabies and their analogs | Cell membrane damage | MTT/MTS assay | CCRF-CEM | Leukemia cancer | IC50 : 32 µM |
| dbacp04488 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | 8402 | Leukemia cancer | IC50 : >150 µg/ml |
| dbacp04491 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MLA | Leukemia cancer | IC50 : >150 µg/ml |
| dbacp04493 | Magainin 2 | GIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | K-562 | Leukemia cancer | IC50 : >150 µg/ml |
| dbacp04506 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | 8402 | Leukemia cancer | IC50 : 18 µg/ml |
| dbacp04509 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MLA | Leukemia cancer | IC50 : 34 µg/ml |
| dbacp04511 | Magainin A | AIGKFLHSAKKFGKAFVGEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | K-562 | Leukemia cancer | IC50 : 40 µg/ml |
| dbacp04516 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | 8402 | Leukemia cancer | IC50 : 12 µg/ml |
| dbacp04519 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MLA | Leukemia cancer | IC50 : 30 µg/ml |
| dbacp04521 | Magainin B | GIGKFLHAAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | K-562 | Leukemia cancer | IC50 : 32 µg/ml |
| dbacp04532 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | 8402 | Leukemia cancer | IC50 : 16 µg/ml |
| dbacp04535 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MLA | Leukemia cancer | IC50 : 33 µg/ml |
| dbacp04537 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | K-562 | Leukemia cancer | IC50 :37 µg/ml |
| dbacp04543 | Malanin chain A | DYPKLTFTTS | Plant sources | Inducing apoptosis | MTT assay | MCF-7 | Leukemia | IC50 : 11.20 ± 0.02 nM |
| dbacp04549 | Malanin chain B | DETCTDEEFN | Plant sources | Inducing apoptosis | MTT assay | MCF-7 | Leukemia | IC50 : 11.20 ± 0.02 nM |
| dbacp04607 | Maximin1 | GIGTKILGGVKTALKGALKELASTYAN | Yunnan firebelly toad | Not specified | MTT/MTS assay | C8166 | Leukemia cancer | IC50 : 15.3 µg/ml |
| dbacp04608 | Maximin1 | GIGTKILGGVKTALKGALKELASTYAN | Yunnan firebelly toad | Not specified | MTT/MTS assay | MOLT-4 | Leukemia cancer | IC50 : 24.3 µg/ml |
| dbacp04611 | Maximin3 | GIGGKILSGLKTALKGAAKELASTYLH | Yunnan firebelly toad | Not specified | MTT/MTS assay | C8166 | Leukemia cancer | IC50 : 11.4 µg/ml |
| dbacp04612 | Maximin3 | GIGGKILSGLKTALKGAAKELASTYLH | Yunnan firebelly toad | Not specified | MTT/MTS assay | MOLT-4 | Leukemia cancer | IC50 : 25.2 µg/ml |
| dbacp04615 | Maximin4 | GIGVLLSAGKAALKGLAKVLAEKYAN | Yunnan firebelly toad | Not specified | MTT/MTS assay | C8166 | Leukemia cancer | IC50 : 24.2 µg/ml |
| dbacp04616 | Maximin4 | GIGVLLSAGKAALKGLAKVLAEKYAN | Yunnan firebelly toad | Not specified | MTT/MTS assay | MOLT-4 | Leukemia cancer | IC50 : 53.4 µg/ml |
| dbacp04619 | Maximin5 | SIGAKILGGVKTFFKGALKELASTYLQ | Yunnan firebelly toad | Not specified | MTT/MTS assay | C8166 | Leukemia cancer | IC50 : 34.4 µg/ml |
| dbacp04620 | Maximin5 | SIGAKILGGVKTFFKGALKELASTYLQ | Yunnan firebelly toad | Not specified | MTT/MTS assay | MOLT-4 | Leukemia cancer | IC50 : >50 µg/ml |
| dbacp04630 | MCL-1, BH3 (208-228) | KALETLRRVGDGVQRNHETAF | Anti apoptotic (MCL-1, BFL1) | Inducing apoptosis | Not specified | Not found | Leukemia | Not found |
| dbacp04683 | Min-Antp-LP4 | KRRMKWKKSWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | CLL | Leukemia | IC50 : 0.3 ± 0.1 µM |
| dbacp04684 | Min-Antp-LP4 | KRRMKWKKSWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | MEC-1 | Leukemia | IC50 : 1.7 ± 0.4 µM |
| dbacp04732 | N-1 | WKLFKKIPKFLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 6 µM |
| dbacp04735 | N-2 | FKLFKKIPKFLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 7 µM |
| dbacp04738 | N-3 | KWFKKIPKFLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 11 µM |
| dbacp04741 | N-3L | KWFKKIPKFLHLLKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 4.2 µM |
| dbacp04744 | N-4 | WFKKIPKFLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 24 µM |
| dbacp04747 | N-4L | WFKKIPKFLHLLKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 3 µM |
| dbacp04750 | N-5 | WKKIPKFLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : < 100 µM |
| dbacp04753 | N-5L | WKKIPKFLHLLKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 :10 µM |
| dbacp04791 | N-Ter-Antp | N-Ter-RQIKIWFQNRRMKWKK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | CLL | Leukemia | IC50 : 3.2 ± 0.5 µM |
| dbacp04792 | N-Ter-Antp | N-Ter-RQIKIWFQNRRMKWKK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | MEC-1 | Leukemia | IC50 : 4.2 ± 0.2 µM |
| dbacp04867 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | NK-lysin | Cell membrane disintegration | PI-uptake assay | SW-480 | Leukemia cancer | LD50 : 1-4 µM |
| dbacp05050 | P18 | KWKFKKIPKFLHLAKKF | Ceropin A | Cell membrane disintegration | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 3.5 µM |
| dbacp05127 | PaDef | ATCETPSKHFNGLCIRSSNCASVCHGEHFTDGRCQGVRRRCMCLKPC | Plant sources | Inducing apoptosis | MTT assay | Jurkat | Leukemia | Not found |
| dbacp05130 | Pal-pFL-N-Ter-TAT | FPWWWPFLRDVFTKGYGFGLGRKKRRQRRRPQ | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | MTT assay | A375 | Leukemia | IC50 : 5.5 ± 1.1 μM |
| dbacp05246 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | AML-2 | Leukemia cancer | Not found |
| dbacp05247 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : > 70 µM |
| dbacp05251 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | AML-2 | Acute myelogenous leukemia | IC50 : > 70 µM |
| dbacp05252 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : > 70 µM |
| dbacp05253 | Pep27 | MRKEFHNVLSSGQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | Jurkat | T-cell leukemia | IC50 : > 70 µM |
| dbacp05257 | Pep27 anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | AML-2 | Acute myelogenous leukemia | IC50 : 50 µM |
| dbacp05258 | Pep27 anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : 53 µM |
| dbacp05259 | Pep27 anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | Jurkat | T-cell leukemia | IC50 : 47 µM |
| dbacp05262 | Pep27 anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | AML-2 | Acute myelogenous leukemia | IC50 : 29 µM |
| dbacp05263 | Pep27 anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : 20 µM |
| dbacp05264 | Pep27 anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Not found | Inducing apoptosis | MTT assay | Jurkat | T cell leukemia | IC50 : 23 µM |
| dbacp05267 | Pep27 anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Not found | Inducing apoptosis | MTT assay | AML-2 | Acute myelogenous leukemia | IC50 : 67 µM |
| dbacp05268 | Pep27 anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Not found | Inducing apoptosis | MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : 52 µM |
| dbacp05269 | Pep27 anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Not found | Inducing apoptosis | MTT assay | Jurkat | T cell leukemia | IC50 : 50 µM |
| dbacp05272 | Pep27 anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Not found | Inducing apoptosis | MTT assay | AML-2 | Acute myelogenous leukemia | IC50 : 50 µM |
| dbacp05273 | Pep27 anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Not found | Inducing apoptosis | MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : 51 µM |
| dbacp05274 | Pep27 anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Not found | Inducing apoptosis | MTT assay | Jurkat | T-cell Leukemia | IC50 : 46 µM |
| dbacp05277 | Pep27 anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Not found | Inducing apoptosis | MTT assay | AML-2 | Acute myelogenous leukemia | IC50 : > 70 µM |
| dbacp05278 | Pep27 anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Not found | Inducing apoptosis | MTT assay | HL-60 | Acute promyelocytic leukemia | IC50 : > 70 µM |
| dbacp05279 | Pep27 anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Not found | Inducing apoptosis | MTT assay | Jurkat | T cell leukemia | IC50 : > 70 µM |
| dbacp05282 | Pep27anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | AML-2 | Leukemia cancer | IC50 : 50 µM |
| dbacp05283 | Pep27anal1 | MWKWFHNVLSSWQLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 53 µM |
| dbacp05287 | Pep27anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | AML-2 | Leukemia cancer | IC50 : 29 µM |
| dbacp05288 | Pep27anal2 | MWKWFHNVLSWWWLLADKRPARDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 20 µM |
| dbacp05292 | Pep27anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | AML-2 | Leukemia cancer | IC50 : 67 µM |
| dbacp05293 | Pep27anal3 | MRKWFHNVLSSGQLLADKWPAWDYNRK | Pneumococcus | Apoptosis inducing | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 52 µM |
| dbacp05297 | Pep27anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Pneumococcus | Apoptosis inducing | MTT/MTS assay | AML-2 | Leukemia cancer | IC50 : 50 µM |
| dbacp05298 | Pep27anal4 | MWKEFHNVLSSGQLLADKRWARWYNRW | Pneumococcus | Apoptosis inducing | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 51 µM |
| dbacp05302 | Pep27anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Pneumococcus | Apoptosis inducing | MTT/MTS assay | AML-2 | Leukemia cancer | IC50 : >70 µM |
| dbacp05303 | Pep27anal5 | MWKWFHNVLSSGQLLADKWWAWWYNWW | Pneumococcus | Apoptosis inducing | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : >70 µM |
| dbacp05322 | Peptide 5 | fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL | Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin | Not specified | MTT/MTS assay | MOLT-4 | Leukemia cancer | 10.4 % inhibition of cell proliferation at 1 nM |
| dbacp05323 | Peptide 5 | fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL | Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin | Not specified | MTT/MTS assay | MOLT-4 | Leukemia cancer | 18.7 % inhibition of cell proliferation at 10 nM |
| dbacp05324 | Peptide 5 | fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL | Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin | Not specified | MTT/MTS assay | MOLT-4 | Leukemia cancer | 34.7 % inhibition of cell proliferation at 100 nM |
| dbacp05325 | Peptide 5 | fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL | Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin | Not specified | MTT/MTS assay | MOLT-4 | Leukemia cancer | 54.3 % inhibition of cell proliferation at 1 µM |
| dbacp05326 | Peptide 5 | fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL | Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin | Not specified | MTT/MTS assay | MOLT-4 | Leukemia cancer | 94.5 % inhibition of cell proliferation at 10 µM |
| dbacp05330 | Peptide 5 | fCYwO-CyLeu-Pen-TKKrPKPfQwFwL-CyLeu-KKLMYPTYLKKfQWAV-Aib-HL | Synthetic peptide of four designed analogs of vasoactive intestinal peptide, bombesin | Not specified | MTT/MTS assay | MOLT-4 | Leukemia cancer | ED50 : 0.29 µM |
| dbacp05397 | Peptide deformylase, mitochondrial | MARLWGALSLWPLWAAVPWGGAAAVGVRACSSTAAPDGVEGPALRRSYWRHLRRLVLGPPEPPFSHVCQVGDPVLRGVAAPVERAQLGGPELQRLTQRLVQVMRRRRCVGLSAPQLGVPRQVLALELPEALCRECPPRQRALRQMEPFPLRVFVNPSLRVLDSRLVTFPEGCESVAGFLACVPRFQAVQISGLDPNGEQVVWQASGWAARIIQHEMDHLQGCLFIDKMDSRTFTNVYWMKVND | Human | Anti-proliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | HL60 | Leukemia | IC50 ± SD : 9.3 ± 2.9 μM |
| dbacp05434 | Peptide-1 | IELLQARGGC-Pem | Synthetic construct | Cell membrane disintegration | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 2.17 µM |
| dbacp05436 | Peptide-2 | IELLQARGGC-Pem-GGRRRRRRRR | Synthetic construct | Cell membrane disintegration | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 2.64 µM |
| dbacp05438 | Peptide-20 | CSSRTMHHC | Synthetic Peptide | Inducing apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | At 100 µM 90% viablity |
| dbacp05445 | Peptide-3 | RRRRRRRRGGC-Pem | Synthetic construct | Cell membrane disintegration | MTT/MTS assay | HL-60 | Leukemia cancer | IC50 : 6.24 µM |
| dbacp05596 | Polyphemusin II | RRWCFRVCYKGFCYRKCR-NH2 | Atlantic horseshoe crab | Induce necrotic cell death | Cell viability assay | K562 | Human erythroleukemia | EC50 : 22 μM |
| dbacp05651 | Protein farnesyltransferase subunit beta | MASSSSFTYYCPPSSSPVWSEPLYSLRPEHARERLQDDSVETVTSIEQAKVEEKIQEVFSSYKFNHLVPRLVLQREKHFHYLKRGLRQLTDAYECLDASRPWLCYWILHSLELLDEPIPQIVATDVCQFLELCQSPDGGFGGGPGQYPHLAPTYAAVNALCIIGTEEAYNVINREKLLQYLYSLKQPDGSFLMHVGGEVDVRSAYCAASVASLTNIITPDLFEGTAEWIARCQNWEGGIGGVPGMEAHGGYTFCGLAALVILKKERSLNLKSLLQWVTSRQMRFEGGFQGRCNKLVDGCYSFWQAGLLPLLHRALHAQGDPALSMSHWMFHQQALQEYILMCCQCPAGGLLDKPGKSRDFYHTCYCLSGLSIAQHFGSGAMLHDVVMGVPENVLQPTHPVYNIGPDKVIQATTHFLQKPVPGFEECEDAVTSDPATD | Rat | Anti-proliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | HL60 | Leukemia | IC50 : 9.3 ± 2.9 μM |
| dbacp05696 | Psychrophilin D (1) | lw | Blue or green mold | Not specified | Cell viability assay | P-388 | Leukemia cancer | ID50 : 10.1 µg/ml |
| dbacp05934 | Retro | LGGIVSAVKKIVDFLG | Amphibian skin secretions | Penetration and disruption of the membranes | Sulforhodamine B assay | Leukemia tumor cell line | Leukemia cancer | IC50 : 5 M |
| dbacp06033 | Scolopendrasin VII | FCTCNVKGFNAKNKRGIIYP | Chinese red-headed centipede, Asia | Necrotic cell death | MTS assay | U937 | Leukemia | Not found |
| dbacp06034 | Scolopendrasin VII | FCTCNVKGFNAKNKRGIIYP | Chinese red-headed centipede, Asia | Necrotic cell death | MTS assay | Jurkat | Leukemia | Not found |
| dbacp06075 | Shiva-1 | MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG | African clawed frog | Pore formation at the cytoplasmic membrane | MTT/MTS assay | K-562 | Leukemia cancer | IC50 : 28.7 µM |
| dbacp06082 | Short α-helical peptide | GIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | 100% Cytotoxicity at 4µM approx. |
| dbacp06083 | Short α-helical peptide | GIIKKIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | 90% Cytotoxicity at 4µM approx. |
| dbacp06084 | Short α-helical peptide | GIIKKIIKKIIKKIIKKI | Alpha-helical proteins | Cell membrane disruption; Cell apoptosis | MTT/MTS assay | HL-60 | Leukemia cancer | 70% Cytotoxicity at 5µM approx. |
| dbacp06123 | SK84 | SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK | Fruit fly | Destroying the cell membranes | Cell proliferation assay | THP-1 | Human Leukemia | MIC : 4 – 8 mM |
| dbacp06301 | Tf-D-LP4 | HAIYPRHSWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | CLL | Leukemia | IC50 : 1.2 ± 0.1 µM |
| dbacp06302 | Tf-D-LP4 | HAIYPRHSWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | MEC-1 | Leukemia | IC50 : 1.8 ± 0.2 µM |
| dbacp06303 | Tf-LP4 | HAIYPRHSWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | CLL | Leukemia | IC50 : 1.7 ± 0.2 µM |
| dbacp06304 | Tf-LP4 | HAIYPRHSWTWEKKLETAVNLAWTAGNSNKWTWK | VDAC1(voltage-dependent anion channel1) | Inducing apoptosis | Not specified | MEC-1 | Leukemia | IC50 : 3.6 ± 0.2 µM |
| dbacp06464 | Varv peptide B (Varv B; Plant defensin) | GLPVCGETCFGGTCNTPGCSCDPWPMCSRN | Field pansy | Not specified | Nonclonogenic fluorometric microculture cytotoxicity assay | Not found | Leukemia | Not found |
| dbacp06465 | Varv peptide C (Varv C; Plant defensin) | GVPICGETCVGGTCNTPGCSCSWPVCTRN | Field pansy | Not specified | Nonclonogenic fluorometric microculture cytotoxicity assay | Not found | Leukemia | Not found |
| dbacp06466 | Varv peptide D (Varv D; Plant defensin) | GLPICGETCVGGSCNTPGCSCSWPVCTRN | Field pansy | Not specified | Nonclonogenic fluorometric microculture cytotoxicity assay | Not found | Leukemia | Not found |
| dbacp06475 | Varv peptide F | GVPICGETCTLGTCYTAGCSCSWPVCTRN | Field pansy | Cell membrane disintegration | Not specified | Not found | Leukemia cancer | Not found |
| dbacp06476 | Varv peptide F | GVPICGETCTLGTCYTAGCSCSWPVCTRN | Field pansy | Cell membrane disintegration | Not specified | Not found | Leukemia cancer | Not found |
| dbacp06482 | Varv peptide G (Varv G; Plant defensin) | GVPVCGETCFGGTCNTPGCSCDPWPVCSRN | Field pansy | Not specified | Nonclonogenic fluorometric microculture cytotoxicity assay | Not found | Leukemia | Not found |
| dbacp06483 | Varv peptide H (Varv H; Plant defensin) | GLPVCGETCFGGTCNTPGCSCETWPVCSRN | Field pansy | Not specified | Nonclonogenic fluorometric microculture cytotoxicity assay | U251 | Leukemia | IC50 : 44.70 µg/mL |
| dbacp06484 | Varv peptide H (Varv H; Plant defensin) | GLPVCGETCFGGTCNTPGCSCETWPVCSRN | Field pansy | Not specified | Nonclonogenic fluorometric microculture cytotoxicity assay | MDA-MB-231 | Leukemia | IC50 : >10 µg/mL |
| dbacp06485 | Varv peptide H (Varv H; Plant defensin) | GLPVCGETCFGGTCNTPGCSCETWPVCSRN | Field pansy | Not specified | Nonclonogenic fluorometric microculture cytotoxicity assay | A549 | Leukemia | IC50 : >10 µg/mL |
| dbacp06486 | Varv peptide H (Varv H; Plant defensin) | GLPVCGETCFGGTCNTPGCSCETWPVCSRN | Field pansy | Not specified | Nonclonogenic fluorometric microculture cytotoxicity assay | DU145 | Leukemia | IC50 : >10 µg/mL |
| dbacp06487 | Varv peptide H (Varv H; Plant defensin) | GLPVCGETCFGGTCNTPGCSCETWPVCSRN | Field pansy | Not specified | Nonclonogenic fluorometric microculture cytotoxicity assay | BEL-7402 | Leukemia | IC50 : >10 µg/mL |
| dbacp06494 | Vibi E | GIPCAESCVWIPCTVTALIGCGCSNKVCYN | Alpine violet, Viola biflora | Cell membrane disintegration | Not specified | Not found | Leukemia cancer | Not found |
| dbacp06532 | VS-9 | VKLRSLLCS | Plant sources | Inducing apoptosis | MTT assay | MOLT4 | Leukemia | Not found |
| dbacp06533 | VS-9 | VKLRSLLCS | Plant sources | Inducing apoptosis | MTT assay | K562 | Leukemia | Not found |
| dbacp06558 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | 8402 | Leukemia cancer | IC50 : 83 µg/ml |
| dbacp06560 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Daudi | Leukemia cancer | IC50 : 143 µg/ml |
| dbacp06561 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | MLA | Leukemia cancer | IC50 : 102 µg/ml |
| dbacp06563 | Z24 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | K-562 | Leukemia cancer | IC50 : 112 µg/ml |
| dbacp06574 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | 8402 | Leukemia cancer | IC50 : 60 µg/ml |
| dbacp06577 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | MLA | Leukemia cancer | IC50 : 80 µg/ml |
| dbacp06579 | Z44 | ALSKALSKALSKALSKALSKALSK | African clawed frog | Dissipate ion gradients;Induce osmotic lysis; Membrane damage | Trypan blue assay | K-562 | Leukemia cancer | IC50 : 98 µg/ml |
| dbacp06752 | Salamandrin - I | FAVWGCADYRGY | Salamandra salamandra | Pyroptosis mediated | MTT assay | HL-60 | Leukemia Cancer | IC50 = 27 µM |
| dbacp06753 | Salamandrin - I | FAVWGCADYRGY | Salamandra salamandra | Pyroptosis mediated | LDH leakage assay | HL-60 | Leukemia Cancer | Absorbance ~ 2 at 490 nm at 27 27 µM |
| dbacp06807 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | K-562 | Leukemia Cancer | CC50 = 6.4 ± 0.6 μM |
| dbacp06808 | [C/U, G1K, L5Y, K8R]cGm | KURRYUYRQRUVTYURGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | HL-60 | Leukemia Cancer | CC50 = 33.3 ±7.4μM |
| dbacp06813 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | K-562 | Leukemia Cancer | CC50 = 1.3 ± 0.1 μM |
| dbacp06814 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | HL-60 | Leukemia Cancer | CC50 = 15.7 ±1.1μM |
| dbacp06818 | [D-P L-P]cGm | GCRRLCYKQRCVTYCRGpPR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | K-562 | Leukemia Cancer | CC50 = 3.9 ± 0.2 μM |
| dbacp06823 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | K-562 | Leukemia Cancer | CC50 = 1.4 ± 0.2 μM |
| dbacp06824 | [C/U]cGm | GURRLUYKQRUVTYURGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | HL-60 | Leukemia Cancer | CC50 = 38.5 ± 4.8 μM |
| dbacp06829 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | K-562 | Leukemia Cancer | CC50 = 2.1 ± 0.2 μM |
| dbacp06830 | [G1K, K8R]cGm | KCRRLCYRQRCVTYCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | HL-60 | Leukemia Cancer | CC50 = 9.0 ± 1.1μM |
| dbacp06835 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | K-562 | Leukemia Cancer | CC50 = 11.5 ± 0.6 μM |
| dbacp06836 | [R4A, R18A]cGm | GCRALCYKQRCVTYCRGA | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | HL-60 | Leukemia Cancer | CC50 = 34.1 ± 3.9 μM |
| dbacp06841 | [Y7W, K8R, Y14W]cGm | GCRRLCWRQRCVTWCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | K-562 | Leukemia Cancer | CC50 = 3.9 ± 0.1 μM |
| dbacp07807 | cT1 | KWCFRVCYRGICYRRCRG | Synthetic | Not Available | Resazurin dye assay | K-562 | Leukemia Cancer | CC50 = 2.0 ± 0.1 µM |
| dbacp07812 | [R/K]cT1 | KWCFKVCYKGICYKKCKG | Synthetic | Not Available | Resazurin dye assay | K-562 | Leukemia Cancer | CC50 = 2.5 ± 0.1 µM |
| dbacp07818 | [W2S]cT1 | KSCFRVCYRGICYRRCRG | Synthetic | Not Available | Resazurin dye assay | K-562 | Leukemia Cancer | CC50 = 2.7 ± 0.2 µM |
| dbacp07823 | [Y8S-I11S]cT1 | KWCFRVCSRGSCYRRCRG | Synthetic | Not Available | Resazurin dye assay | K-562 | Leukemia Cancer | CC50 = 13.2 ± 0.9 µM |
| dbacp07837 | [R9S-R14S-R17S]cT1 | KWCFRVCYSGICYSRCSG | Synthetic | Not Available | Resazurin dye assay | K-562 | Leukemia Cancer | CC50 = 4.8 ± 0.3 µM |
| dbacp07841 | [G18K]cT1 | KWCFRVCYRGICYRRCRK | Synthetic | Not Available | Resazurin dye assay | K-562 | Leukemia Cancer | CC50 = 1.7 ± 0.1 µM |
| dbacp07846 | [I11F-G18K]cT1 | KWCFRVCYRGFCYRRCRK | Synthetic | Not Available | Resazurin dye assay | K-562 | Leukemia Cancer | CC50 = 1.9 ± 0.1 µM |
| dbacp08089 | B1 | KKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562 | Leukemia Cancer | IC50 = 17.9 ± 1.4 μM |
| dbacp08092 | B1 | KKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562/ADM | Leukemia Cancer | IC50 = 19.1 ± 2.1 μM |
| dbacp08093 | B2 | KKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562 | Leukemia Cancer | IC50 = 33.6 ± 4.2 μM |
| dbacp08096 | B2 | KKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562/ADM | Leukemia Cancer | IC50 = 39.6 ± 5.7 μM |
| dbacp08097 | B3 | KKLFKKILKYLKKL | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562 | Leukemia Cancer | IC50 = 47.4 ± 12.5 μM |
| dbacp08100 | B5 | LKKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562 | Leukemia Cancer | IC50 = 26.5 ± 1.5 μM |
| dbacp08103 | B5 | LKKLFKKILKYLK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562/ADM | Leukemia Cancer | IC50 = 28.3 ± 2.3 μM |
| dbacp08104 | B6 | LKKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562 | Leukemia Cancer | IC50 = 19.2 ± 2.3 μM |
| dbacp08107 | B6 | LKKLFKKILKYLKK | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562/ADM | Leukemia Cancer | IC50 = 22.7 ± 2.3 μM |
| dbacp08108 | B9 | KLKKLFKKILKY | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562 | Leukemia Cancer | IC50 = 60.7 ± 5.4 μM |
| dbacp08111 | B9 | KLKKLFKKILKY | Analogue of BP 100 | Membrane disruption triggers apoptosis | MTT assay | K-562/ADM | Leukemia Cancer | IC50 = 83.7 ± 5.3 μM |
| dbacp08349 | LPSBD-0 | CQYSVNPKIKRFELYFKGRMW | Synthetic | Not Available | Not Available | THP-1 | Leukemia Cancer | Not Available |
| dbacp08350 | LPSBD-2 | CHYRVKPKIKRFEKYKGRMW | Synthetic | Not Available | Not Available | THP-1 | Leukemia Cancer | Not Available |
| dbacp08377 | IDP-wtL05 | RKRRNDLRSRFLALRDQ | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | RPMI | Leukemia Cancer | EC50 ~ 10 μM |
| dbacp08378 | IDP-LS05 | RKRRNDLRSRFLALRDQ | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | HL-60 | Leukemia Cancer | EC50 ~ 5 μM |
| dbacp08379 | IDP-LS05 | RKRRNDLRSRFLALRDQ | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | RPMI | Leukemia Cancer | EC50 ~ 6 μM |
| dbacp08381 | IDP-LS13 | RKRRNDLRSRFLALRDQ | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | HL-60 | Leukemia Cancer | EC50 ~ 7 μM |
| dbacp08382 | IDP-LS13 | RKRRNDLRSRFLALRDQ | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | RPMI | Leukemia Cancer | EC50 ~ 9 μM |
| dbacp08384 | IDP-LS15 | RKRRNDLRSRFLALRDQ | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | RPMI | Leukemia Cancer | EC50 ~ 7 μM |
| dbacp08386 | IDP-LS16 | APKVVILSKALEYLQA | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | RPMI | Leukemia Cancer | EC50 ~ 15 μM |
| dbacp08388 | IDP-LS17 | APKVVILSKALEYLQA | Synthetic | Not Available | MTT/Alamamar-Blue/Hexosaminidase activity test | RPMI | Leukemia Cancer | EC50 ~ 10 μM |